DT-EQUIPMENT-EHF
4.9.2020 11:45:04 CEST | Business Wire | Press release
DT Equipment ehf. (DTE) (www.dtequipment.com ), developers of next-generation analytics technology for metals production and processing, announced today the close of a Series A financing with the new participation of Chrysalix Venture Capital and follow-on investment from Brunnur Ventures.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200904005232/en/
Sveinn Gudmundsson, CEO of DTE commented, “We are delighted to welcome Chrysalix onboard as industry-focused investors who not only bring a wealth of both technical and early-stage business-building experience to the table, but do so with a highly collaborative and collegiate joint-team approach. We look forward to continuing to working closely together to further advance our world-leading analytics technologies for metal production and processing, and bringing these to market for customers worldwide.”
Chrysalix Venture Capital is a global venture capital fund with a long history of commercializing step-change innovation for resource intensive industries. The Chrysalix RoboValley Fund invests in intelligent systems enabled by AI, IoT and sensor technologies to achieve significant improvements in productivity and critical business processes. Investors in the fund include Fortune 500 companies, leading corporates, financial institutions, family offices and universities, and a notable cluster of metals producers, such as South32, Severstal and Mitsubishi Corporation.
“Chrysalix is making metals and mining innovation, with resource productivity and intelligent systems, a major theme of our new fund. Working with our strategic investors and high potential start-ups, we accelerate new step-change solutions into the mainstream market,” said Richard MacKellar, Managing Partner at Chrysalix Venture Capital. “DTE’s technology enables accurate real-time sampling of liquid metal in primary and secondary aluminum production. Compositional information in real-time results in increased production and quality, reduced costs, and energy savings for aluminum producers. This is in line with our investment thesis of using intelligent systems to improve the economics, efficiency and environmental sustainability of resource intensive industries, while creating significant value for customers.”
DTE was founded in 2013 by highly experienced aluminum industry professionals, with a vision to transform metals production and processing with next-generation sensors and analytics. Based in Iceland, DTE addresses the high unmet need to complement and replace current slow, expensive and manual methods for process and quality control with real-time, in-line analysis of trace materials. DTE’s platform combines first-in-industry fully automated elemental analyzers, generating real-time data, reference quality elemental composition direct from liquid metal with a powerful software analytics platform for pro-active and predictive process control. Watch our technology in action at https://www.dtequipment.com/liquid-metal-analyzer
Aura Capital Partners acted as corporate advisor to the Company.
About DT Equipment
DTE, based in Reykjavik, Iceland is focused on next-generation industrial metal production process control, towards Industry 4.0. The Company’s flagship DTE-EA product range provides first-in-industry direct sampling and compositional analysis of molten metal, addressing the high unmet need to complement and replace current slow, expensive and manual methods for process and quality control with real-time, in-line analysis of trace materials. Real-time process feedback offers substantial opportunities, including improved production efficiency, energy and process cost savings from faster, more frequent measurements and improved operator safety through limiting the need for human intervention. For more information please visit www.dtequipment.com .
About Chrysalix Venture Capital
Chrysalix is a technology focused venture capital firm that builds, mentors and connects high growth companies. Founded in Vancouver, Canada in 2001, and with offices in Delft, Netherlands, Chrysalix has built its reputation on bringing disruptive innovation to the world’s largest industries by focusing on where technology meets physical science. The firm’s investments include breakthrough technologies like smart mining, 3D printing of steel, fast charging electric vehicle infrastructure, emissions-free solar steam, battery intelligence, C02 capture, wastewater management, and fusion energy. Chrysalix has one of the strongest investment teams in the industry with deep energy, technology and entrepreneurial expertise, and is backed by more than 20 international blue chip industrial and financial investors. Chrysalix latest fund, the Chrysalix RoboValley Fund, is the firm’s second fund under management focused on industrial innovation and is expected to grow to over $120M. For more information please visit: www.chrysalix.com or contact Allison Johnson at ajohnson@chrysalix.com .
About Brunnur Ventures
Brunnur Ventures is a $30m venture capital fund focused on Icelandic start-up companies, emphasizing innovation and growth, combined with scalable business models and extraordinary entrepreneurial talent. The Fund is managed by Brunnur Ventures GP. For more information please visit: www.brunnurventures.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005232/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom